Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis

被引：0

作者：

Fox, E. ^{[1
]}

Steinman, L. ^{[2
]}

Hartung, H. ^{[3
,4
,5
,6
]}

Alvarez, E. ^{[7
]}

Qian, P. ^{[8
]}

Wray, S. ^{[9
]}

Robertson, D. ^{[10
]}

Huang, D. ^{[11
]}

Selmaj, K. ^{[12
]}

Wynn, D. ^{[13
]}

Weiss, M. S. ^{[14
]}

Bosco, J. A. ^{[14
]}

Power, S. A. ^{[14
]}

Mok, K. A. ^{[14
]}

Lee, L. ^{[14
]}

Cree, B. A. ^{[15
]}

机构：

[1] Cent Texas Neurol Consultants, Round Rock, TX USA

[2] Stanford Univ, Stanford, CA 94305 USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[5] Med Univ Vienna, Vienna, Austria

[6] Palacky Univ, Olomouc, Czech Republic

[7] Univ Colorado, Aurora, CO USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Hope Neurol, Knoxville, TN USA

[10] Univ S Florida, Tampa, FL 33620 USA

[11] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA

[12] Univ Warmia & Mazury, Ctr Neurol, Lodz, Poland

[13] Consultants Neurol, Northbrook, IL USA

[14] TG Therapeut Inc, New York, NY USA

[15] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P105

引用

页码：68 / 68

页数：1

共 50 条

[41] Ofatumumab: a novel monoclonal anti-CD20 antibody
Lin, Thomas S.
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
[42] Anti-CD20 antibody wows in multiple sclerosis
Sheridan, Cormac
NATURE BIOTECHNOLOGY, 2015, 33 (12) : 1215 - 1216
[43] Subcutaneous anti-CD20 targeted B cell depletion preserves memory B cells and IgG serum levels in patients with relapsing remitting multiple sclerosis
Haase, Stefanie
Krickl, Anna-Lena
Freudenstein, David
Burner, Felix
Angstwurm, Klemens
Lee, De-Hyung
Linker, Ralf
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 335 - 336
[44] Anti-CD20 antibody wows in multiple sclerosis
Cormac Sheridan
Nature Biotechnology, 2015, 33 : 1215 - 1216
[45] Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS
Fox, Edward J.
Lovett-Racke, Amy
Gormley, Matthew
Liu, Yue
Petracca, Maria
Inglese, Matilde
Cocozza, Sirio
Wray, Sibyl
Shubin, Richard
Bosco, Jenna A.
Power, Sean A.
Weiss, Michael
Mok, Koby
Eubanks, James L.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 49 - 49
[46] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
Fox, E.
Wray, S.
Shubin, R.
Lovett-Racke, A.
Huang, D.
Bass, A.
Weiss, M.
Power, S.
Bosco, J.
Mok, K.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544
[47] Assessing B-cell depletion and disease activity in a french multiple sclerosis cohort treated by long-term anti-CD20 antibody therapy
Freeman, S.
Lemarchant, B.
Alberto, T.
Drelon, A.
Boucher, J.
Dubucquoi, S.
Zephir, H.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 355 - 356
[48] A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Sawas, Ahmed
Farber, Charles M.
Schreeder, Marshall T.
Khalil, Mazen Y.
Mahadevan, Daruka
Deng, Changchun
Amengual, Jennifer E.
Nikolinakos, Petros G.
Kolesar, Jill M.
Kuhn, John G.
Sportelli, Peter
Miskin, Hari P.
O'Connor, Owen A.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 243 - 253
[49] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
Deng, Changchun
Amengual, Jennifer Effie
Schreeder, Marshall T.
Clark-Garvey, Sean
Patterson, Molly
Miskin, Hari
Sportelli, Peter
O'Connor, Owen A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs
Huang, Deren
Alvarez, Enrique
Miskin, Hari
Lee, Lily
Foley, John
NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →